Carmustine Nano-Suspension for Reduced Acute Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional lyophilized formulations of carmustine exhibit high toxicity and low selectivity due to rapid degradation and poor water solubility, limiting their application in cancer treatment.
Innovation Solution
Development of novel drug delivery systems in the form of nano-suspension and micro-emulsion, utilizing poly(lactic-co-glycolic acid) (PLGA) and surfactants, which are stable at 2-8°C for at least 3 months, allowing for controlled drug release and improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lyophilized formulation of carmustine is used, then the drug can be administered, but it causes high toxicity and rapid degradation with no intact drug detectable after 15 minutes
Solution Approach 1:
The patent segments the carmustine molecule into nanoscale particles (50-500 nm) suspended in a protective medium. This segmentation allows the drug to maintain structural integrity longer in the bloodstream while reducing acute toxicity effects, addressing both the reliability of therapeutic efficacy and the harmful toxicity factors simultaneously
Solution Approach 2:
The patent introduces an intermediary protective medium (such as polymers or lipids) that surrounds and protects the carmustine molecules. This intermediary layer prevents rapid degradation and reduces direct interaction with blood components that cause toxicity, thereby maintaining therapeutic efficacy while reducing harmful effects
2Ease of manufacture
If carmustine is administered as lyophilized powder requiring reconstitution, then the drug can be delivered, but it exhibits poor water solubility and rapid hydrolysis at pH>6
Solution Approach 1:
The patent changes the physical parameters of carmustine by formulating it as nanosuspension with controlled particle size (50-500 nm) and adjusting the pH of the formulation to below 6. This parameter change prevents hydrolysis while maintaining ease of manufacture, resolving the contradiction between formulation stability and drug stability
Solution Approach 2:
The patent creates a composite formulation combining carmustine nanoparticles with stabilizing excipients and protective matrices. This composite structure enhances both the ease of manufacture and the stability of the drug composition, preventing hydrolysis while maintaining formulation integrity
3Productivity
If conventional carmustine formulation is used, then the drug can be administered intravenously, but it shows low selectivity and rapid tissue absorption with no intact drug after 15 minutes
Solution Approach 1:
The patent segments carmustine into nanoscale particles that can be selectively delivered to tumor sites through the EPR effect. This segmentation improves both productivity (enhanced tumor accumulation) and reliability (selectivity), as the nanoscale particles preferentially accumulate in tumor tissues while reducing non-specific tissue absorption
Solution Approach 2:
The patent transitions from conventional bulk drug formulation to nanoscale particle formulation, adding a dimensional aspect (nanoscale size) that enables selective permeation through biological barriers. This dimensional change improves both drug delivery efficiency and selectivity by exploiting size-dependent transport mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel drug delivery systems demonstrate significant tumor regression and reduced acute toxicity, maintaining therapeutic effects for extended periods while minimizing side effects.
Implementation Method 1
The composition comprises an organic phase and an aqueous phase, wherein the organic phase further comprises poly (lactic-co-glycolic acid) (PLGA) dissolved in suitable organic solvents and aqueous phase further comprises one or more surfactants dissolved in water for injection
Implementation Method 2
the organic phase further comprises poly (lactic-co-glycolic acid) (PLGA) dissolved in suitable organic solvents
Implementation Method 3
allowing for controlled drug release and improved therapeutic efficacy
Implementation Method 4
In another embodiment the novel drug delivery system of the present invention is in the form of micro-emulsion
Implementation Method 5
aqueous phase further comprises one or more surfactants dissolved in water for injection
Data Source
AI summary
The present invention relates to a composition comprising nitrosourea and pharmaceutically acceptable excipients. In particular, the present invention relates to novel drug delivery systems of carmustine such as nano-suspension and micro-emulsion and its use for the treatment of cancer by intravenous administration. Also provided are methods for preparation of such novel drug delivery systems.